Daniel
Wagner
Senior Managing Director, Investments

bio

Dan is responsible for evaluating investment opportunities, structuring investments and monitoring portfolio companies through active board participation. Dan has led or assisted with CI’s investments in AxioMx (acquired by Abcam); Affomix (acquired by Illumina); CyVek (acquired by Bio-Techne); Cara Therapeutics (NASDAQ: CARA); HistoRx (acquired by Genoptix); Melinta Therapeutics, formerly Rib-X (NASDAQ: MLNT); RemoteReality (acquired by RTI); Biohaven Pharmaceuticals (NYSE:  BHVN); and Arvinas (NASDAQ: ARVN).

Dan contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by successful former CI portfolio company CuraGen Corporation. While at CuraGen, Dan held a variety of scientific and operational management positions in research and development, technology assessment and implementation of next-generation scientific technologies that supported CuraGen’s growth from a genomic and proteomic platform company into a biopharmaceutical firm dedicated to advancing its protein, antibody and small-molecule therapeutics.

connect
education
  • B.S., Biology, University of Dayton
  • M.H.S., Biomedical Sciences, Quinnipiac University
  • M.B.A., Finance, Quinnipiac University
Companies
  • Allomek (Board)
  • Azitra (Board)
  • Biorez (Board)
  • CavtheRx (Board Observer)
  • Cornovus Pharmaceuticals (Board)
  • Cybrexa (Board Observer)
  • EpiEP, Inc. (Board)
  • IsoPlexis (Board)
  • KLEO (Board Observer)
  • Medically Home Group (Board Observer)
  • Mitotherapeutics (Board)
  • P2 Science (Board)
  • Tangen Biosciences (Board)
Interesting Facts
  • Favorite place: Water (beach/pool)
  • Favorite pastime: Spending time with family